ClinicalTrials.gg
CompletedNCT01987479OSCARUpdated Jun 19, 2017Results posted

A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis

A Phase 3 interventional study of Non-Biologic DMARDs and Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 20 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-19.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
36th of 110
150 · median 97
Started
2014
with 8 others
Phase 3
65 of 110
none open now
Registered
79th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 36th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 79th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multi-center, open-label single arm Phase IIIb study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab administered as monotherapy and/or in combination with methotrexate or other non-biologic disease modifying antirheumatic drugs (DMARDs) in participants with rheumatoid arthritis (RA) with an inadequate response to non-biologic DMARDs.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria.
  • Oral (≤10 mg/day prednisone or equivalent), nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic DMARDs are permitted if on a stable dose regimen for greater than or equal to (≥]) 4 weeks prior to Baseline.
  • Use of effective throughout the study as defined by protocol; female participants of cannot be pregnant.

Exclusion criteria

Exclusion Criteria:

  • Presence of medical conditions.
  • History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower gastrointestinal disease that might predispose to perforation.
  • Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections.
  • Any infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening.
  • Clinically significant findings on laboratory tests.
  • Positive surface antigen or antibody.
  • Active tuberculosis requiring treatment within the previous 3 years.
  • Evidence of active malignant disease, diagnosed within the previous 10 years, or breast cancer diagnosed within the previous 20 years.
  • History of alcohol, drug, or chemical abuse within 1 year prior to Screening.
  • Neuropathies or other conditions that might interfere with pain evaluation.
  • Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline.
  • Rheumatic disease other than RA, including systemic lupus erythematosis, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjögren's syndrome with RA is permitted.
  • Functional Class IV as defined by the ACR Classification of Functional Status in RA.
  • Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age of 16 years.
  • Prior history of or current inflammatory joint disease other than RA.
  • Exposure to tocilizumab (either intravenous or SC) at any time prior to Baseline.
  • Treatment with any agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of Screening.
  • Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
  • Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline.
  • Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Tocilizumab Alone or in Combination with Methotrexate or DMARD

    Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.

    Drug: Non-Biologic DMARDs · Drug: Tocilizumab · Drug: Methotrexate

Interventions

  • DrugNon-Biologic DMARDs

    Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.

  • Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.

    Also known as: RoActemra, Actemra

  • Methotrexate will be administered per investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Adverse events included serious as well as non-serious adverse events.

    Time frame: Baseline up to Week 32

Secondary outcomes

  1. Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

    DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR less than or equal to (≤) 3.2 implied low disease activity and greater than (\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 implied clinical remission.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  2. Percentage of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response

    A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  3. Percentage of Participants Achieving an ACR50 Response

    A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  4. Percentage of Participants Achieving an ACR70 Response

    A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  5. Percentage of Participants Achieving an ACR90 Response

    A participant had an ACR90 response if there was at least a 90% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  6. Percentage of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR

    DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  7. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

    The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity .

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  8. Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 16, 20, 24, and Early Withdrawal

    The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  9. Change From Baseline in Total TJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

    Number of tender joints was determined by examining 28 joints for TJC28 and 68 joints for TJC68, and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 for a TJC28 and 68 for a TJC68. A reduction in number of tender joints compared to baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  10. Change From Baseline in Total SJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

    Number of swollen joints was determined by examination of 28 joints for SJC28 and 66 joints for SJC66 and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 for a SJC28 and 66 for a SJC66. A reduction in number of swollen joints compared to baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)

  11. Percentage of Participants With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Dose Reductions or Discontinuation Categorized by Reasons

    Results are reported for percentage of participants who had NSAIDs dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).

    Time frame: From Week 16 and before Week 20; From Week 20 and before Week 24

  12. Percentage of Participants With Corticosteroid Dose Reductions or Discontinuation Categorized by Reasons

    Results are reported for percentage of participants who had corticosteroid dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).

    Time frame: From Week 16 and before Week 20; From Week 20 and before Week 24

  13. Time to Discontinuation or First Dose Reduction of Corticosteroids or NSAIDs

    Time to discontinuation or first dose reduction of corticosteroids or NSAIDs (weeks) = (Date of the first dose reduction or end date of corticosteroids or NSAIDs treatment - date of first drug intake of this study) + 1. Time to discontinuation or first dose reduction was based on the first occurring event (corticosteroid discontinuation or corticosteroid first dose reduction or NSAIDs discontinuation or NSAIDs first dose reduction, whichever occurred first).

    Time frame: Baseline up to Week 32

  14. Percentage of Participants With Anti-Tocilizumab Antibodies

    Time frame: Baseline, Weeks 12 and 24, early withdrawal (up to Week 24), follow-up visit (8 weeks after last dose of tocilizumab, up to 32 weeks)

  15. Serum Levels of Tocilizumab

    Time frame: Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)

  16. Serum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)

    Time frame: Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)

  17. Patient Global Assessment of Disease Activity VAS Scores

    Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)

  18. Patient Pain VAS Scores

    This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)

  19. Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)

  20. Percentage of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records

    A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)

  21. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

    The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)

07

Results

Posted Jun 19, 2017

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab Alone or in Combination With Methotrexate or DMARD
Started150
Completed133
Not completed17
Withdrew: Protocol violation1
Withdrew: Physician decision2
Withdrew: Participant/legal guardian decision1
Withdrew: Other5
Withdrew: Lost to follow-up1
Withdrew: Adverse event7

Outcome measures

PrimaryPercentage of Participants With Adverse Events

An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Adverse events included serious as well as non-serious adverse events.

Time frame:
Baseline up to Week 32
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Percentage of Participants With Adverse Events91.3
SecondaryChange From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR less than or equal to (≤) 3.2 implied low disease activity and greater than (\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 implied clinical remission.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
units on a scaleTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=150)4.8 ± 1.3
Change at Week 2 (n=148)1.337 ± 0.989
Change at Week 4 (n=144)2.037 ± 0.991
Change at Week 8 (n=136)2.635 ± 1.098
Change at Week 12 (n=133)2.908 ± 1.135
Change at Week 16 (n=128)3.014 ± 1.240
Change at Week 20 (n=122)3.169 ± 1.170
Change at Week 24 (n=121)3.232 ± 1.247
Change at early withdrawal visit (n=27)1.653 ± 1.562
SecondaryPercentage of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response

A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Week 2 (n=148)20.3 ± 0.989
Week 4 (n=144)40.3 ± 0.991
Week 8 (n=136)58.1 ± 1.098
Week 12 (n=133)69.9 ± 1.135
Week 16 (n=130)71.5 ± 1.240
Week 20 (n=123)78.9 ± 1.170
Week 24 (n=121)82.6 ± 1.247
Early withdrawal visit (n=27)37.0 ± 1.562
SecondaryPercentage of Participants Achieving an ACR50 Response

A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR50 Response
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Week 2 (n=148)6.1 ± 0.989
Week 4 (n=144)18.1 ± 0.991
Week 8 (n=136)33.1 ± 1.098
Week 12 (n=133)43.6 ± 1.135
Week 16 (n=130)52.3 ± 1.240
Week 20 (n=123)54.5 ± 1.170
Week 24 (n=121)62.0 ± 1.247
Early withdrawal visit (n=27)18.5 ± 1.562
SecondaryPercentage of Participants Achieving an ACR70 Response

A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR70 Response
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Week 2 (n=148)1.4 ± 0.989
Week 4 (n=144)6.9 ± 0.991
Week 8 (n=136)14.0 ± 1.098
Week 12 (n=133)21.1 ± 1.135
Week 16 (n=130)29.2 ± 1.240
Week 20 (n=123)38.2 ± 1.170
Week 24 (n=121)35.5 ± 1.247
Early withdrawal visit (n=27)14.8 ± 1.562
SecondaryPercentage of Participants Achieving an ACR90 Response

A participant had an ACR90 response if there was at least a 90% improvement, ie, reduction from Baseline, in TJC and SJC (28 assessed joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ACR90 Response
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Week 2 (n=148)0.0 ± 0.989
Week 4 (n=144)1.4 ± 0.991
Week 8 (n=136)2.9 ± 1.098
Week 12 (n=133)6.8 ± 1.135
Week 16 (n=130)9.2 ± 1.240
Week 20 (n=123)11.4 ± 1.170
Week 24 (n=121)15.7 ± 1.247
Early withdrawal visit (n=27)3.7 ± 1.562
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR

DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Week 2: Good response (n=148)34.5 ± 0.989
Week 2: Moderate response (n=148)41.9 ± 0.991
Week 2: No response (n=148)23.6 ± 1.098
Week 4: Good response (n=144)59.7 ± 1.135
Week 4: Moderate response (n=144)34.0 ± 1.240
Week 4: No response (n=144)6.3 ± 1.170
Week 8: Good response (n=136)78.7 ± 1.247
Week 8: Moderate response (n=136)17.6 ± 1.562
Week 8: No response (n=136)3.7
Week 12: Good response (n=133)85.0
Week 12: Moderate response (n=133)12.0
Week 12: No response (n=133)3.0
Week 16: Good response (n=128)89.1
Week 16: Moderate response (n=128)7.0
Week 16: No response (n=128)3.9
Week 20: Good response (n=122)91.8
Week 20: Moderate response (n=122)5.7
Week 20: No response (n=122)2.5
Week 24: Good response (n=121)92.6
Week 24: Moderate response (n=121)5.0
Week 24: No response (n=121)2.5
Early withdrawal visit: Good response (n=27)44.4
Early withdrawal visit: Moderate response (n=27)29.6
Early withdrawal visit: No response (n=27)25.9
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity .

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
units on a scaleTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=145)26.03 ± 12.55
Change at Week 2 (n=97)-6.2 ± 7.4
Change at Week 4 (n=78)-11.3 ± 8.0
Change at Week 8 (n=64)-14.4 ± 9.2
Change at Week 12 (n=63)-17.2 ± 10.8
Change at Week 16 (n=67)-18.5 ± 11.1
Change at Week 20 (n=57)-19.7 ± 11.2
Change at Week 24 (n=56)-19.9 ± 11.8
Change at early withdrawal visit (n=18)-8.0 ± 10.7
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 16, 20, 24, and Early Withdrawal

The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 16, 20, 24, and Early Withdrawal
units on a scaleTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=150)24.32 ± 11.84
Change at Week 2 (n=148)-4.7 ± 7.3
Change at Week 4 (n=144)-9.4 ± 7.2
Change at Week 8 (n=135)-13.4 ± 8.7
Change at Week 12 (n=132)-15.4 ± 9.2
Change at Week 16 (n=129)-16.7 ± 10.1
Change at Week 20 (n=122)-17.8 ± 10.2
Change at Week 24 (n=121)-18.3 ± 11.1
Change at early withdrawal visit (n=27)-6.4 ± 10.3
SecondaryChange From Baseline in Total TJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

Number of tender joints was determined by examining 28 joints for TJC28 and 68 joints for TJC68, and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 for a TJC28 and 68 for a TJC68. A reduction in number of tender joints compared to baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Mean · tender joints
Change From Baseline in Total TJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
tender jointsTocilizumab Alone or in Combination With Methotrexate or DMARD
TJC28: Baseline (n=150)7.7 ± 6.5
TJC28: Change at Week 2 (n=148)-1.38 ± 3.71
TJC28: Change at Week 4 (n=144)-2.94 ± 3.89
TJC28: Change at Week 8 (n=136)-4.33 ± 4.82
TJC28: Change at Week 12 (n=133)-4.68 ± 5.05
TJC28: Change at Week 16 (n=130)-5.36 ± 5.55
TJC28: Change at Week 20 (n=123)-5.79 ± 5.24
TJC28: Change at Week 24 (n=121)-5.96 ± 5.67
TJC28: Change at early withdrawal visit (n=27)-1.07 ± 4.59
TJC68: Baseline (n=150)13.2 ± 10.0
TJC68: Change at Week 2 (n=148)-2.40 ± 5.84
TJC68: Change at Week 4 (n=144)-5.15 ± 6.25
TJC68: Change at Week 8 (n=136)-7.19 ± 7.57
TJC68: Change at Week 12 (n=133)-7.98 ± 8.46
TJC68: Change at Week 16 (n=130)-9.45 ± 9.07
TJC68: Change at Week 20 (n=123)-9.86 ± 9.04
TJC68: Change at Week 24 (n=121)-10.02 ± 8.94
TJC68: Change at early withdrawal visit (n=27)-1.93 ± 8.53
SecondaryChange From Baseline in Total SJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal

Number of swollen joints was determined by examination of 28 joints for SJC28 and 66 joints for SJC66 and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 for a SJC28 and 66 for a SJC66. A reduction in number of swollen joints compared to baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and at Early Withdrawal (up to Week 24)
Reported as:
Mean · swollen joints
Change From Baseline in Total SJC at Weeks 2, 4, 8, 12, 16, 20, 24, and Early Withdrawal
swollen jointsTocilizumab Alone or in Combination With Methotrexate or DMARD
SJC28: Baseline (n=150)6.2 ± 5.4
SJC28: Change at Week 2 (n=148)-1.18 ± 3.04
SJC28: Change at Week 4 (n=144)-2.44 ± 3.33
SJC28: Change at Week 8 (n=136)-3.62 ± 3.86
SJC28: Change at Week 12 (n=133)-4.24 ± 4.17
SJC28: Change at Week 16 (n=130)-4.61 ± 4.14
SJC28: Change at Week 20 (n=123)-4.92 ± 4.24
SJC28: Change at Week 24 (n=121)-5.23 ± 4.63
SJC28: Change at early withdrawal visit (n=27)-1.33 ± 4.18
SJC66: Baseline (n=150)9.1 ± 7.3
SJC66: Change at Week 2 (n=148)-1.84 ± 4.16
SJC66: Change at Week 4 (n=144)-3.94 ± 4.35
SJC66: Change at Week 8 (n=136)-5.61 ± 4.74
SJC66: Change at Week 12 (n=133)-6.50 ± 5.79
SJC66: Change at Week 16 (n=130)-6.78 ± 5.95
SJC66: Change at Week 20 (n=123)-7.52 ± 6.44
SJC66: Change at Week 24 (n=121)-7.80 ± 6.86
SJC66: Change at early withdrawal visit (n=27)-2.33 ± 4.89
SecondaryPercentage of Participants With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Dose Reductions or Discontinuation Categorized by Reasons

Results are reported for percentage of participants who had NSAIDs dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).

Time frame:
From Week 16 and before Week 20; From Week 20 and before Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Dose Reductions or Discontinuation Categorized by Reasons
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Unknown reasons (Week 16 to Week 20)0.0
Safety reasons (Week 16 to Week 20)0.7
Other reasons (Week 16 to Week 20)0.7
Lack of efficacy (Week 16 to Week 20)0.0
Discomfort (Week 16 to Week 20)0.0
Unknown reasons (Week 20 to Week 24)0.0
Safety reasons (Week 20 to Week 24)0.0
Other reasons (Week 20 to Week 24)0.0
Lack of efficacy (Week 20 to Week 24)0.0
Discomfort (Week 20 to Week 24)0.0
SecondaryPercentage of Participants With Corticosteroid Dose Reductions or Discontinuation Categorized by Reasons

Results are reported for percentage of participants who had corticosteroid dose reductions or discontinuation by reasons for dose reductions or discontinuation (unknown reasons, safety reasons, other reasons, lack of efficacy, and discomfort).

Time frame:
From Week 16 and before Week 20; From Week 20 and before Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Corticosteroid Dose Reductions or Discontinuation Categorized by Reasons
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Unknown reasons (Week 16 to Week 20)0.0
Safety reasons (Week 16 to Week 20)1.3
Other reasons (Week 16 to Week 20)0.7
Lack of efficacy (Week 16 to Week 20)0.0
Discomfort (Week 16 to Week 20)0.0
Unknown reasons (Week 20 to Week 24)0.0
Safety reasons (Week 20 to Week 24)0.0
Other reasons (Week 20 to Week 24)1.3
Lack of efficacy (Week 20 to Week 24)0.7
Discomfort (Week 20 to Week 24)0.0
SecondaryTime to Discontinuation or First Dose Reduction of Corticosteroids or NSAIDs

Time to discontinuation or first dose reduction of corticosteroids or NSAIDs (weeks) = (Date of the first dose reduction or end date of corticosteroids or NSAIDs treatment - date of first drug intake of this study) + 1. Time to discontinuation or first dose reduction was based on the first occurring event (corticosteroid discontinuation or corticosteroid first dose reduction or NSAIDs discontinuation or NSAIDs first dose reduction, whichever occurred first).

Time frame:
Baseline up to Week 32
Reported as:
Median · weeks
Time to Discontinuation or First Dose Reduction of Corticosteroids or NSAIDs
weeksTocilizumab Alone or in Combination With Methotrexate or DMARD
Time to Discontinuation or First Dose Reduction of Corticosteroids or NSAIDs25.3 (25.0 to 28.0)
SecondaryPercentage of Participants With Anti-Tocilizumab Antibodies
Time frame:
Baseline, Weeks 12 and 24, early withdrawal (up to Week 24), follow-up visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Tocilizumab Antibodies
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=147)6.1 ± 0.5906
Week 12 (n=5)40.0 ± 0.5734
Week 24 (n=121)7.4 ± 0.5587
Early withdrawal (n=22)9.1 ± 0.5330
Follow-up visit (n=26)11.5 ± 0.5682
SecondarySerum Levels of Tocilizumab
Time frame:
Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Serum Levels of Tocilizumab
micrograms per milliliter (mcg/mL)Tocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=4)0.5 ± 0.3
Week 12 (n=123)42.3 ± 25.2
Week 24 (n=112)46.5 ± 29.2
Early withdrawal (n=17)16.8 ± 19.3
Follow-up visit (n=3)60.9 ± 29.7
SecondarySerum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)
Time frame:
Baseline, Weeks 12 and 24, Early Withdrawal (up to Week 24), Follow-up Visit (8 weeks after last dose of tocilizumab, up to 32 weeks)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Serum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)
nanograms per milliliter (ng/mL)Tocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=139)38.3 ± 10.4
Week 12 (n=126)516.6 ± 137.7
Week 24 (n=115)536.5 ± 161.6
Early withdrawal (n=21)380.4 ± 215.2
Follow-up visit (n=26)117.5 ± 194.3
SecondaryPatient Global Assessment of Disease Activity VAS Scores

Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)
Reported as:
Mean · mm
Patient Global Assessment of Disease Activity VAS Scores
mmTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=150)54.8 ± 22.3
Week 2 (n=148)43.6 ± 23.0
Week 4 (n=144)35.5 ± 23.0
Week 8 (n=136)27.2 ± 21.8
Week 12 (n=133)22.2 ± 20.3
Week 16 (n=129)21.3 ± 21.0
Week 20 (n=123)19.2 ± 18.6
Week 24 (n=121)18.8 ± 19.5
Early withdrawal (n=27)40.4 ± 30.9
SecondaryPatient Pain VAS Scores

This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and Early withdrawal (up to Week 24)
Reported as:
Mean · mm
Patient Pain VAS Scores
mmTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=150)52.5 ± 22.1
Week 2 (n=148)44.4 ± 21.9
Week 4 (n=144)35.8 ± 22.3
Week 8 (n=136)27.6 ± 21.3
Week 12 (n=133)21.7 ± 19.0
Week 16 (n=129)20.9 ± 20.2
Week 20 (n=123)19.5 ± 18.0
Week 24 (n=121)19.6 ± 18.8
Early withdrawal (n=27)42.8 ± 30.4
SecondaryHealth Assessment Questionnaire-Disability Index (HAQ-DI) Score

The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
Reported as:
Mean · units on a scale
Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
units on a scaleTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=147)1.2329 ± 0.5708
Week 2 (n=147)1.0978 ± 0.5906
Week 4 (n=143)0.9673 ± 0.5734
Week 8 (n=134)0.8249 ± 0.5587
Week 12 (n=131)0.7460 ± 0.5330
Week 16 (n=129)0.6996 ± 0.5682
Week 20 (n=122)0.6620 ± 0.5333
Week 24 (n=119)0.6681 ± 0.5745
Early withdrawal (n=27)1.2315 ± 0.6853
SecondaryPercentage of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records

A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
Reported as:
Number · percentage of participants
Percentage of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records
percentage of participantsTocilizumab Alone or in Combination With Methotrexate or DMARD
Week 2 (n=148)90.5 ± 0.5906
Week 4 (n=144)95.8 ± 0.5734
Week 8 (n=136)91.9 ± 0.5587
Week 12 (n=133)97.7 ± 0.5330
Week 16 (n=130)93.8 ± 0.5682
Week 20 (n=123)95.1 ± 0.5333
Week 24 (n=121)92.6 ± 0.5745
Early withdrawal (n=27)88.9 ± 0.6853
SecondaryFunctional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, and early withdrawal (up to Week 24)
Reported as:
Mean · units on a scale
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
units on a scaleTocilizumab Alone or in Combination With Methotrexate or DMARD
Baseline (n=133)29.84 ± 9.43
Week 2 (n=134)33.07 ± 9.34
Week 4 (n=133)35.10 ± 10.37
Week 8 (n=126)37.34 ± 9.25
Week 12 (n=126)37.89 ± 8.52
Week 16 (n=122)37.93 ± 9.11
Week 20 (n=118)39.65 ± 8.87
Week 24 (n=114)39.93 ± 8.65
Early withdrawal (n=27)33.48 ± 12.06

Adverse events

Collected over Baseline up to Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab Alone or in Combination With Methotrexate or DMARD—14/150 (9.3%)77/150 (51.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventTocilizumab Alone or in Combination With Methotrexate or DMARD
AppendicitisInfections and infestations1/150
Arthritis bacterialInfections and infestations1/150
Skin infectionInfections and infestations1/150
Scapula fractureInjury, poisoning and procedural complications1/150
Tibia fractureInjury, poisoning and procedural complications1/150
ArthralgiaMusculoskeletal and connective tissue disorders1/150
Joint range of motion decreasedMusculoskeletal and connective tissue disorders1/150
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/150
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/150
PsoriasisSkin and subcutaneous tissue disorders1/150
Most frequent other events
Most frequent other events
EventTocilizumab Alone or in Combination With Methotrexate or DMARD
NasopharyngitisInfections and infestations35/150
NauseaGastrointestinal disorders18/150
FatigueGeneral disorders18/150
DizzinessNervous system disorders11/150
DiarrhoeaGastrointestinal disorders9/150
RashSkin and subcutaneous tissue disorders8/150
LeukopeniaBlood and lymphatic system disorders8/150
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/150

Baseline characteristics

Full Analysis Set (FAS) population included all participants who received at least one dose of SC tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab Alone or in Combination With Methotrexate or DMARD
Mean55.85 ± 11.20
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab Alone or in Combination With Methotrexate or DMARD
Female110
Male40
08

Study locations

20 sites
  • ZGT Almelo; Reumatologie
    Almelo, 7609 PP, Netherlands
  • Jan Van Breemen Instituut
    Amsterdam, 1056 AB, Netherlands
  • Gelre Ziekenhuizen; Reumatologie
    Apeldoorn, 7334 DZ, Netherlands
  • Amphia ziekenhuis, locatie langendijk
    Breda, 4819 EV, Netherlands
  • Albert Schweitzer Ziekenhuis ; Dordwijk
    Dordrecht, 3318AT, Netherlands
  • Universitair Medisch Centrum Groningen; Department of Rheumatology
    Groningen, 9700RB, Netherlands
  • Martini Ziekenhuis
    Groningen, 9728 MG, Netherlands
  • Kennemer Gasthuis
    Haarlem, 2035 RC, Netherlands
  • Atrium Medisch Centrum
    Heerlen, 6419 PC, Netherlands
  • Spaarne Ziekenhuis; Inwendige Geneeskunde
    Hoofddorp, 2134 TM, Netherlands
  • Medisch Centrum Leeuwarden; Reumatology
    Leeuwarden, 8934 AD, Netherlands
  • Academisch Ziekenhuis Leiden; Dept of Rheumatology
    Leiden, 2333 ZA, Netherlands
  • Maastricht University Medical Centre; Rheumatology
    Maastricht, 6202 ZA, Netherlands
  • Erasmus Medisch Centrum; Reumatologie
    Rotterdam, 3015 CE, Netherlands
  • Maasstadziekenhuis; Reumatologie
    Rotterdam, 3079 DZ, Netherlands
  • Vlietland Hospital
    Schiedam, 3118 JH, Netherlands
  • Antonius Ziekenhuis Sneek; Department of Rheumatology
    Sneek, 8601 ZK, Netherlands
  • Leyenburg Ziekenhuis; Internal Medecine
    The Hague, 2545 CH, Netherlands
  • St. Bronovo-Nebo
    The Hague, 2597 AX, Netherlands
  • University Medical Centre Utrecht; Reumatologie en Klinische Immunologie
    Utrecht, 3584 GA, Netherlands
09

References and documents

Publications

  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in May 2016, 27 months.

Results were first posted in Jun 2017, 1 year after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 27 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2013
First posted
Nov 19, 2013
StartActual
Jan 30, 2014
Primary completionActual
May 26, 2016
CompletionActual
May 26, 2016
Results first posted
Jun 19, 2017
Last update
Jun 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01987479
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Jan 30, 2014
Primary completion
May 26, 2016
Completion
May 26, 2016
Results posted
Jun 19, 2017
Last update
Jun 19, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Methotrexate

Start the discussion